Company profile: Talecris
1.1 - Company Overview
Company description
- Provider of plasma-derived protein therapies, produced and marketed by a biopharmaceutical company founded in 2004 and based in Barcelona, Spain.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Talecris
InnoPharma
HQ: United States
Website
- Description: Provider of niche-generic, specialty pharmaceutical and bio-pharmaceutical product development, operating as a privately held pharmaceutical R&D company founded in 2005 and based in Piscataway, New Jersey.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full InnoPharma company profile →
CoGenesys
HQ: United States
Website
- Description: Provider of peptide- and protein-based medicine development for cancer, cardiovascular, metabolic, infectious, autoimmune, and CNS diseases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CoGenesys company profile →
LEAF Pharmaceuticals
HQ: United States
Website
- Description: Provider of biotechnology and healthcare products, including investigational anticancer drugs targeting solid tumors (LEAF-1401, LEAF-1701) with preclinical results showing reduced metastatic tumor burden in lung cancer models, superior performance in colorectal models, and minimal myelosuppression and gastrointestinal toxicity, plus LEAF-1404, a complex generic anticancer medicine manufactured under global cGMP.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full LEAF Pharmaceuticals company profile →
Halia Therapeutics
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies for inflammatory and neurodegenerative disorders, including HT-6184, a novel NEK7/NLRP3 inhibitor in Phase II for lower-risk myelodysplastic syndromes and post-procedure diagnostic biomarkers of inflammation and pain. Pipeline includes NEK7 inhibitors to block NLRP3 inflammasome assembly and LRRK2 inhibitors for diseases such as Parkinson's and Alzheimer's.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Halia Therapeutics company profile →
DJS Antibodies
HQ: United Kingdom
Website
- Description: Provider of antibody therapeutics and discovery technology targeting GPCRs to treat chronic inflammatory and fibrotic diseases. Offers HEPTAD, a proprietary platform to discover functional, first-in-class antibodies for complex protein targets; DJS 001, a first-in-class program for myeloid cell driven inflammatory disease; and DJS 002, a monoclonal antibody for fibrotic diseases without off-target side effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full DJS Antibodies company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Talecris
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Talecris
2.2 - Growth funds investing in similar companies to Talecris
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Talecris
4.2 - Public trading comparable groups for Talecris
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →